S&P 500   4,586.60 (+1.63%)
DOW   34,709.24 (+2.02%)
QQQ   389.32 (+0.57%)
AAPL   162.93 (-1.12%)
MSFT   330.15 (+0.02%)
FB   309.00 (-0.52%)
GOOGL   2,859.77 (+1.37%)
AMZN   3,444.00 (+0.01%)
TSLA   1,077.00 (-1.64%)
NVDA   322.16 (+2.48%)
BABA   120.26 (-1.82%)
NIO   34.59 (-9.71%)
CGC   9.95 (+0.10%)
AMD   150.17 (+0.71%)
GE   95.16 (+2.32%)
MU   82.77 (-2.80%)
T   23.11 (+3.96%)
F   19.83 (+1.28%)
DIS   146.27 (+2.90%)
PFE   53.33 (-2.47%)
AMC   29.73 (+4.06%)
ACB   5.96 (-0.83%)
BA   198.49 (+5.47%)
S&P 500   4,586.60 (+1.63%)
DOW   34,709.24 (+2.02%)
QQQ   389.32 (+0.57%)
AAPL   162.93 (-1.12%)
MSFT   330.15 (+0.02%)
FB   309.00 (-0.52%)
GOOGL   2,859.77 (+1.37%)
AMZN   3,444.00 (+0.01%)
TSLA   1,077.00 (-1.64%)
NVDA   322.16 (+2.48%)
BABA   120.26 (-1.82%)
NIO   34.59 (-9.71%)
CGC   9.95 (+0.10%)
AMD   150.17 (+0.71%)
GE   95.16 (+2.32%)
MU   82.77 (-2.80%)
T   23.11 (+3.96%)
F   19.83 (+1.28%)
DIS   146.27 (+2.90%)
PFE   53.33 (-2.47%)
AMC   29.73 (+4.06%)
ACB   5.96 (-0.83%)
BA   198.49 (+5.47%)
S&P 500   4,586.60 (+1.63%)
DOW   34,709.24 (+2.02%)
QQQ   389.32 (+0.57%)
AAPL   162.93 (-1.12%)
MSFT   330.15 (+0.02%)
FB   309.00 (-0.52%)
GOOGL   2,859.77 (+1.37%)
AMZN   3,444.00 (+0.01%)
TSLA   1,077.00 (-1.64%)
NVDA   322.16 (+2.48%)
BABA   120.26 (-1.82%)
NIO   34.59 (-9.71%)
CGC   9.95 (+0.10%)
AMD   150.17 (+0.71%)
GE   95.16 (+2.32%)
MU   82.77 (-2.80%)
T   23.11 (+3.96%)
F   19.83 (+1.28%)
DIS   146.27 (+2.90%)
PFE   53.33 (-2.47%)
AMC   29.73 (+4.06%)
ACB   5.96 (-0.83%)
BA   198.49 (+5.47%)
S&P 500   4,586.60 (+1.63%)
DOW   34,709.24 (+2.02%)
QQQ   389.32 (+0.57%)
AAPL   162.93 (-1.12%)
MSFT   330.15 (+0.02%)
FB   309.00 (-0.52%)
GOOGL   2,859.77 (+1.37%)
AMZN   3,444.00 (+0.01%)
TSLA   1,077.00 (-1.64%)
NVDA   322.16 (+2.48%)
BABA   120.26 (-1.82%)
NIO   34.59 (-9.71%)
CGC   9.95 (+0.10%)
AMD   150.17 (+0.71%)
GE   95.16 (+2.32%)
MU   82.77 (-2.80%)
T   23.11 (+3.96%)
F   19.83 (+1.28%)
DIS   146.27 (+2.90%)
PFE   53.33 (-2.47%)
AMC   29.73 (+4.06%)
ACB   5.96 (-0.83%)
BA   198.49 (+5.47%)
NASDAQ:TXMD

TherapeuticsMD Stock Forecast, Price & News

$0.48
+0.02 (+5.33%)
(As of 12/2/2021 01:56 PM ET)
Add
Compare
Today's Range
$0.44
$0.49
50-Day Range
$0.46
$0.79
52-Week Range
$0.45
$2.75
Volume
111,307 shs
Average Volume
8.30 million shs
Market Capitalization
$204.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.79
30 days | 90 days | 365 days | Advanced Chart
Receive TXMD News and Ratings via Email

Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter.


TherapeuticsMD logo

About TherapeuticsMD

TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. It also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.

Headlines

Therapeuticsmd Insider Trades $580K In Company Stock
November 22, 2021 |  finance.yahoo.com
TherapeuticsMD (NASDAQ:TXMD) Issues Earnings Results
November 12, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TXMD
Previous Symbol
NYSEMKT:TXMD
Employees
400
Year Founded
N/A

Sales & Book Value

Annual Sales
$64.87 million
Book Value
($0.41) per share

Profitability

Net Income
$-183.52 million
Net Margins
-188.82%
Pretax Margin
-184.85%

Debt

Price-To-Earnings

Miscellaneous

Free Float
386,521,000
Market Cap
$204.20 million
Optionable
Optionable

Company Calendar

Last Earnings
11/11/2021
Today
12/02/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/01/2022

MarketRank

Overall MarketRank

2.23 out of 5 stars

Medical Sector

353rd out of 1,391 stocks

Pharmaceutical Preparations Industry

153rd out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions

Is TherapeuticsMD a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TherapeuticsMD stock.
View analyst ratings for TherapeuticsMD
or view top-rated stocks.

How has TherapeuticsMD's stock price been impacted by COVID-19 (Coronavirus)?

TherapeuticsMD's stock was trading at $1.52 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TXMD stock has decreased by 68.4% and is now trading at $0.4799.
View which stocks have been most impacted by COVID-19
.

When is TherapeuticsMD's next earnings date?

TherapeuticsMD is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022.
View our earnings forecast for TherapeuticsMD
.

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD, Inc. (NASDAQ:TXMD) issued its quarterly earnings results on Thursday, November, 11th. The company reported ($0.11) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.01. During the same period in the prior year, the business posted ($0.10) EPS.
View TherapeuticsMD's earnings history
.

What price target have analysts set for TXMD?

2 Wall Street analysts have issued 12-month price objectives for TherapeuticsMD's shares. Their forecasts range from $3.00 to $5.00. On average, they expect TherapeuticsMD's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 733.5% from the stock's current price.
View analysts' price targets for TherapeuticsMD
or view top-rated stocks among Wall Street analysts.

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the following people:

What other stocks do shareholders of TherapeuticsMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Cleveland-Cliffs (CLF), Novavax (NVAX) and Micron Technology (MU).

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

Who are TherapeuticsMD's major shareholders?

TherapeuticsMD's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.97%), Morgan Stanley (1.97%), Geode Capital Management LLC (1.65%), Rubric Capital Management LP (1.26%), Sanders Morris Harris LLC (0.84%) and Renaissance Technologies LLC (0.35%). Company insiders that own TherapeuticsMD stock include Cooper C Collins, Edward Borkowski, James Darecca, Marlan D Walker, Michael C Donegan, Michael C Donegan, Paul Bisaro, Robert G Finizio, Tommy G Thompson and Tommy G Thompson.
View institutional ownership trends for TherapeuticsMD
.

Which institutional investors are selling TherapeuticsMD stock?

TXMD stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Millennium Management LLC, Knights of Columbus Asset Advisors LLC, Raymond James & Associates, Squarepoint Ops LLC, Alliancebernstein L.P., Citigroup Inc., and GSA Capital Partners LLP. Company insiders that have sold TherapeuticsMD company stock in the last year include Edward Borkowski, James Darecca, Marlan D Walker, Michael C Donegan, and Robert G Finizio.
View insider buying and selling activity for TherapeuticsMD
or view top insider-selling stocks.

Which institutional investors are buying TherapeuticsMD stock?

TXMD stock was bought by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, Renaissance Technologies LLC, Brandywine Global Investment Management LLC, Geode Capital Management LLC, Cubist Systematic Strategies LLC, BlackRock Inc., Goldman Sachs Group Inc., and Barclays PLC. Company insiders that have bought TherapeuticsMD stock in the last two years include Cooper C Collins, Paul Bisaro, Robert G Finizio, and Tommy G Thompson.
View insider buying and selling activity for TherapeuticsMD
or or view top insider-buying stocks.

How do I buy shares of TherapeuticsMD?

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TherapeuticsMD's stock price today?

One share of TXMD stock can currently be purchased for approximately $0.48.

How much money does TherapeuticsMD make?

TherapeuticsMD has a market capitalization of $203.39 million and generates $64.87 million in revenue each year. The company earns $-183.52 million in net income (profit) each year or ($0.48) on an earnings per share basis.

How many employees does TherapeuticsMD have?

TherapeuticsMD employs 400 workers across the globe.

What is TherapeuticsMD's official website?

The official website for TherapeuticsMD is www.therapeuticsmd.com.

Where are TherapeuticsMD's headquarters?

TherapeuticsMD is headquartered at 951 Yamato Road Suite 220, BOCA RATON FL, 33431.

How can I contact TherapeuticsMD?

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The company can be reached via phone at (561) 961-1900, via email at [email protected], or via fax at 561-431-3389.


This page was last updated on 12/2/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.